Karen Wagner
InvestorGeneral Partner at Ysios Capital · Board director at KALA BIO
Zurich
Writes $1M – $7.5M checks · typically $1M
About
Karen Wagner is a Managing Partner at Ysios Capital, where she works on therapeutic investments and helps identify and evaluate opportunities. She joined Ysios in 2008 after more than a decade in biotech and pharma business development, having begun her career as a management consultant in McKinsey & Company's healthcare practice and later served as Director of Business Development at Ingenium Pharmaceuticals. She previously worked at Glycart Biotechnology and, following its acquisition by F. Hoffmann-La Roche, led business development and alliance management at Roche; she holds a Master's in Molecular Biology and a PhD in Cell Biology from the University of Konstanz.
Contact· self-published, not guessed
Invests in
Biotech
Board director at KALA BIO
Intro paths
In turn, Karen can intro founders to KALA BIO's investors below.
KALA BIO's investors · 7
Co-founders at KALA BIO
Experience
- Ysios CapitalGeneral Partnercurrent2007 — present
- Independent ConsultantConsultant Business Development2007 — 2014
- F. Hoffmann-La Roche LtdGlobal Alliance Director2005 — 2007
- GlycArt Biotechnology AGVP Licensing2004 — 2005
- Ingenium Pharmaceuticals AGDirector Business Development2001 — 2004
- McKinsey & CompanyConsultant1998 — 2001
Skills & more
From Karen's professional profile.
Investments
Board seats
AELIX TherapeuticsCardozCytoki PharmaGalectoKala PharmaceuticalsMinoryx TherapeuticsSparingVision’s websiteSynendosVivet TherapeuticsXeltis
Per the firm's website.
Colleagues at Ysios Capital
Network1
Investors connected to Karen in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Karen Wagner?
- Karen Wagner is a Managing Partner at Ysios Capital, where she works on therapeutic investments and helps identify and evaluate opportunities. She joined Ysios in 2008 after more than a decade in biotech and pharma business development, having begun her career as a management consultant in McKinsey & Company's healthcare practice and later served as Director of Business Development at Ingenium Pharmaceuticals. She previously worked at Glycart Biotechnology and, following its acquisition by F. Hoffmann-La Roche, led business development and alliance management at Roche; she holds a Master's in Molecular Biology and a PhD in Cell Biology from the University of Konstanz.
- Where does Karen Wagner work?
- Karen Wagner is General Partner at Ysios Capital and Board director at KALA BIO.
- What does Karen Wagner invest in?
- Karen Wagner invests in Biotech.
- What check size does Karen Wagner write?
- Karen Wagner typically writes checks of $1M – $7.5M.
- What boards does Karen Wagner sit on?
- Karen Wagner holds tracked board seats at AELIX Therapeutics, Cardoz, Cytoki Pharma, Galecto, Kala Pharmaceuticals, Minoryx Therapeutics, SparingVision’s website, Synendos, Vivet Therapeutics, Xeltis.
- Where did Karen Wagner go to school?
- Karen Wagner studied at University of Konstanz (PhD, Molecular and Cell Biology).
Same school
Also attended University of Konstanz22
+ 16 more
Shared employers
Also worked at F. Hoffmann-La Roche Ltd109
+ 103 more
Also worked at GlycArt Biotechnology AG2
Also worked at McKinsey & Company1,879
+ 1,873 more